The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis

(2017) Takahiro Tsujikawa et al.   Cell Reports

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Human IgG4: a structural perspective

(2015) Anna M. Davies et al.   IMMUNOLOGICAL REVIEWS

The S228P Mutation Preventsin Vivoandin VitroIgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation

(2015) John-Paul Silva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

(2015) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions

(2015) Michelle Kinder et al.   mAbs

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer

(2015) Minna M. Boström et al.   PLoS One

Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

(2014) Peter J. Murray et al.   IMMUNITY

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcγRI

(2014) Jennifer FA Swisher et al.   mAbs

A Humanized Mouse Identifies the Bone Marrow as a Niche with Low Therapeutic IgG Activity

(2014) Anja Lux et al.   Cell Reports

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies

(2014) Caitlin Gillis et al.   Frontiers in Immunology

Macrophage Cytokines: Involvement in Immunity and Infectious Diseases

(2014) Guillermo Arango Duque et al.   Frontiers in Immunology

Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment

(2014) Theerawut Chanmee et al.   Cancers

FcγRI is required for TGFβ2-treated macrophage-induced tolerance

(2013) Z. Gu et al.   IMMUNOBIOLOGY

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

Crosstalk between Human IgG Isotypes and Murine Effector Cells

(2012) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature

(2012) Qiong-wen Zhang et al.   PLoS One

Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages

(2011) Q. Zhao et al.   JOURNAL OF IMMUNOLOGY

Functional Characteristics of the High Affinity IgG Receptor, Fc RI

(2011) C. E. van der Poel et al.   JOURNAL OF IMMUNOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Differential signal transduction, membrane trafficking, and immune effector functions mediated by Fc RI versus Fc RIIa

(2009) X. Dai et al.   BLOOD

M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro

(2009) M. Leidi et al.   JOURNAL OF IMMUNOLOGY

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

(2009) Aran F Labrijn et al.   NATURE BIOTECHNOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD